好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Post-neurosurgical CSF Pleocytosis and Hyperproteinorrachia in Brain Tumor Patients
Neuro-oncology
P2 - Poster Session 2 (11:45 AM-12:45 PM)
6-004

To estimate the prevalence of CSF pleocytosis and hyperproteinorrachia after neurological surgery and evaluate their duration and time to normalization.

Post-surgical CSF pleocytosis and protein elevation are often attributed to inflammatory responses, but data supporting this are limited, and the time course for normalization is unknown.

We retrospectively reviewed 221 patients with medulloblastoma treated between 2013 and 2023. Demographic, surgical, and clinical data were abstracted from medical records. CSF samples were analyzed for pleocytosis and protein abnormalities at baseline (first sample after initial surgery) and during follow-up. Primary outcomes included prevalence and time to normalization of CSF indices. Associations with extent of resection, ventriculoperitoneal (VP) shunting, cytology, and metastases were evaluated.

Of 221 patients (63% male, median age 9.5 years, range 3.2–38.6), gross total resection was achieved in 83%, near-total in 11%, and subtotal in 6%; 28% required repeat surgery. Median time from surgery to baseline CSF was 20.0 days (range 6-63). Distant metastases were present in 40%. CSF management included external ventricular drain placement in 46% and VP shunting in 18%. CSF cytology was positive for tumor cells in 15%, and infectious meningitis occurred in 3%. At baseline, 69% demonstrated pleocytosis, more frequent after gross total resection (p=0.039). Of these, 97% normalized (median 150 days, range 4–686), with delayed return to normal associated with VP shunting (p=0.0056) and positive cytology (p=0.0209). Elevated baseline protein occurred in 35%, associated with metastasis (p=0.009), shunting (p=0.001), and positive cytology (p=0.018). Among these, 61% normalized (median 147 days, range 5–1254), with delayed normalization linked to metastasis (p=0.0042), shunting (p<0.0001), and positive cytology (p=0.0099).

 

Postoperative CSF pleocytosis and protein abnormalities are frequent but usually resolve. Delayed normalization is associated with VP shunt, positive cytology, and metastasis. Abnormal CSF may persist in some patients for many months.

 

Authors/Disclosures
Maria Daniela Orellana Zambrano, MD (UTHSC)
PRESENTER
Dr. Orellana Zambrano has nothing to disclose.
Raja B. Khan, MD, FAAN (St. Jude Children'S Research Hospital) Dr. Khan has nothing to disclose.
Kelley M. Rohman, RN Mrs. Rohman has received personal compensation for serving as an employee of St. Jude Children's Research Hospital. An immediate family member of Mrs. Rohman has received personal compensation for serving as an employee of St. Jude Children's Research Hospital.
Andrea Simmons, NP (St. Jude CHildrens' Research Hospital) Ms. Simmons has nothing to disclose.
Mia Lin Ms. Lin has nothing to disclose.
Arzu Onar-Thomas, PhD Dr. Onar-Thomas has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ASCO. The institution of Dr. Onar-Thomas has received research support from Novocure. The institution of Dr. Onar-Thomas has received research support from Treovir. The institution of Dr. Onar-Thomas has received research support from Pediatric Brain Tumor Foundation. The institution of Dr. Onar-Thomas has received research support from Pfizer.
Giles W. Robinson, MD Dr. Robinson has nothing to disclose.
Amar Gajjar, MD Dr. Gajjar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Day One Therapeutics.
Emily Hanzlik, MD (St. Jude Children's Research Hospital) Dr. Hanzlik has received publishing royalties from a publication relating to health care.